Cardiac conduction abnormalities may occur; increased risk in patients with underlying structural disease, preexisting conduction system abnormalities, ischemic heart disease, cardiomyopathies, or concomitant use of PR-interval prolonging drugs; monitoring recommended.
Hepatotoxicity has been reported; risk factors include concomitant use of multiple medications, underlying hepatitis B or C, preexisting liver disease, liver enzyme abnormalities; monitoring recommended.
Lipid disorders, significant increases in total cholesterol and triglycerides, have been reported; monitoring recommended.
Consider monitoring for hyperglycemia and new onset or exacerbation of diabetes mellitus.
Use of oral solution not recommended in preterm neonates in immediate postnatal period unless benefit outweighs risk.